• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Brennan Michelle

    (Last) (First) (Middle)
    C/O MASIMO CORPORATION
    52 DISCOVERY

    (Street)
    IRVINE CA 92618

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MASIMO CORP [ MASI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) X Other (specify below)
    Chairman of the Board
    3. Date of Earliest Transaction (Month/Day/Year)
    08/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/12/2025 P 100 A $150.35(1) 7,218 D
    Common Stock 08/13/2025 P 100 A $155.25(1) 7,318 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person.
    Remarks:
    /s/ Micah W. Young, Attorney-In-Fact 08/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MASI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    1/3/2024Buy → Hold
    Needham
    11/8/2023Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $MASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO, Consumer Division Tripodi Blair exercised 15,000 shares at a strike of $142.13 and covered exercise/tax liability with 8,078 shares, increasing direct ownership by 100% to 13,818 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    9/25/25 6:25:25 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Dadswell Charles

    4 - MASIMO CORP (0000937556) (Issuer)

    9/3/25 5:03:29 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Dadswell Charles

    3 - MASIMO CORP (0000937556) (Issuer)

    9/3/25 5:02:35 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    SEC Filings

    View All

    Masimo Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MASIMO CORP (0000937556) (Filer)

    9/29/25 4:18:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Corporation filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MASIMO CORP (0000937556) (Filer)

    9/23/25 9:02:14 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MASIMO CORP (0000937556) (Filer)

    8/19/25 4:48:07 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $437,940 worth of shares (3,000 units at $145.98), increasing direct ownership by 168% to 4,790 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/12/25 4:20:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HARMAN Completes Sound United Acquisition to Expand Premium Audio Leadership

    Strategic integration of Sound United's award-winning audio brands strengthens HARMAN's product portfolio and propels business growth HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., focused on connected technologies for automotive, consumer, and enterprise markets, today announced it has completed the acquisition of Sound United, the former consumer audio business of Masimo Corporation (NASDAQ:MASI). Sound United's portfolio of iconic audio brands includes Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, HEOS, Classé, and Boston Acoustics. This press release features multimedia. View the full release here: https://www.busin

    9/23/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Completes Sale of Consumer Audio Business to HARMAN International

    Masimo (NASDAQ:MASI) today announced it has completed the previously announced sale of its Sound United consumer audio business to HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd. Katie Szyman, Chief Executive Officer of Masimo, stated, "The completion of the Sound United sale is an important milestone in our ongoing efforts to focus on our core professional healthcare business. With this chapter behind us, we are even better positioned to broaden Masimo's patient impact, accelerate growth, and deliver stronger margins. We have exciting opportunities ahead, and I am confident that we will be able to continue building on our positive momentum to d

    9/23/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs

    Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ:MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/Continuous Patient Monitoring with Masim

    9/17/25 8:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James reiterated coverage on Masimo with a new price target

    Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

    12/27/24 7:29:29 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo upgraded by Raymond James with a new price target

    Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00

    11/6/24 7:17:22 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously

    6/3/24 7:31:43 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Financials

    Live finance-specific insights

    View All

    HARMAN Completes Sound United Acquisition to Expand Premium Audio Leadership

    Strategic integration of Sound United's award-winning audio brands strengthens HARMAN's product portfolio and propels business growth HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., focused on connected technologies for automotive, consumer, and enterprise markets, today announced it has completed the acquisition of Sound United, the former consumer audio business of Masimo Corporation (NASDAQ:MASI). Sound United's portfolio of iconic audio brands includes Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, HEOS, Classé, and Boston Acoustics. This press release features multimedia. View the full release here: https://www.busin

    9/23/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Reports Second Quarter 2025 Results

    Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $371 million, representing 8% growth on a reported basis; Non-GAAP revenue of $370 million, representing 7% growth on a constant currency basis(2); GAAP net income per diluted share of $0.82; and Non-GAAP net income per diluted share(2) of $1.33, which grew 46% versus prior year period. Katie Szyman, Chief Executive Officer of Masimo, said, "We once again delivered strong results in the second quarter as our core health care business continued to demonstrate strong growth and earnings. W

    8/5/25 4:05:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered partic

    7/22/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    9/25/24 4:01:23 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    8/30/24 4:56:53 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    7/17/24 5:29:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Leadership Updates

    Live Leadership Updates

    View All

    Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

    American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

    7/8/25 8:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments